Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer

  1. Pivot, X.
  2. Pegram, M.
  3. Cortes, J.
  4. Lüftner, D.
  5. Lyman, G.H.
  6. Curigliano, G.
  7. Bondarenko, I.
  8. Yoon, Y.C.
  9. Kim, Y.
  10. Kim, C.
Zeitschrift:
European Journal of Cancer

ISSN: 1879-0852,  0959-8049

Datum der Publikation: 2019

Ausgabe: 120

Seiten: 1-9

Art: Artikel

DOI: 10.1016/J.EJCA.2019.07.015 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus